Yong Liu - SINOPHARM Insider

SINOPHARM -- Hong Kong Stock  

HKD 34.95  0.1  0.29%

Chief Legal Advisor and VP

Mr. Liu Yong was appointed as the Secretary to the Board and Joint Company Secretary of Sinopharm Group Co., Ltd. He has over 22 years of working experience, over 19 years of which is management experience in the pharmaceutical and healthcare products industry. Mr. Liu obtained a bachelors degree in science, majoring in business administration of pharmaceutical enterprises, from China Pharmaceutical University in July 1992 and a masters degree in business administration from Fudan University in January 2000. Mr. Liu is a chief pharmacist and a practicing pharmacist. Mr. Liu was employed at Shanghai Pharmaceutical station from July 1992 to July 1999, and served as the deputy general manager at the marketing department of China National Pharmaceutical Group Shanghai Corporationrationration and the deputy general manager of Shanghai Guoda Drug Chain Store Co., Ltd. from July 1999 to April 2003. Mr. Liu is currently the chairman of Sinopharm Holding Beijing Tianxingpuxin BioMed Co., Ltd., Sinopharm Holding Beijing Co., Ltd., Sinopharm Holding Beijing Kangchen Biomedicine Co., Ltd., Sinopharm Holding Guoda Drug Stores Co., Ltd., Sinopharm Holding Guizhou Co., Ltd., Sinopharm Holding Yunnan Co., Ltd., Sinopharm Medicine Holding Beijing Huahong Co., Ltd., and the director of China National Medicines Co., Ltd. and Sichuan Pharmaceutical Group Co., Ltd. of CNPGC.
Age: 46  VP Since 2016      
86 21 2305 2666  http://www.sinopharmholding.com/En

Management Efficiency

The company has return on total asset (ROA) of 3.96 % which means that it generated profit of $3.96 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 14.59 % meaning that it generated $14.59 on every $100 dollars invested by stockholders.
The company has accumulated 6.5 B in total debt with debt to equity ratio (D/E) of 90.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. SINOPHARM has Current Ratio of 1.23 suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due.

Entity Summary

Sinopharm Group Co.Ltd., together with its subsidiaries, distributes pharmaceutical and healthcare solutions in the People?s Republic of China. SINOPHARM (1099) is traded on Hong Kong Stock Exchange in Hong Kong. It is located in Sinopharm Group Co., Ltd.Shanghai, and employs 55,869 people.

Did you try this?

Run Portfolio Reporting Now

Portfolio Reporting

Create custom reports across your portfolios and generate quick suggestion pitch
Hide  View All  Next  Launch Portfolio Reporting
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add SINOPHARM to your portfolio

Top Management

SINOPHARM Leadership Team
Jindong Deng, Director
Hailiang Liu, Director
Tze Yu, Director
Fang Yao, Executive
Guangpu Li, President
Yong Liu, VP
Qunbin Wang, Director
Yuhua Li, Director
Bin Zhou, Director
Junyu Guo, President
Lulin She, Chairman
Ping Ma, Director
Wanyong Lian, Executive
Qiyu Chen, Director
Ling Li, Director
Deyong Wen, Director
Zhiming Li, President
Zheng Liu, Director
Fumin Zhuo, Director
Xiuchang Jiang, CFO
Wee Tan, Director
Jun Lu, President
Yulin Wei, President
Chang Lyu, Director
Yijian Wu, Director
Wanjun Ma, President
Guangfu Li, President
Dongjiu Li, Director
Shuangjun Xu, President
Wei Liu, Executive, Ph.D
Zhongxi Cai, President, Ph.D
Qi Chen, Chairman

Stock Performance

SINOPHARM Performance Indicators